#USA #Carlsbad #ALZpath #pTau217 #Alzheimer

ALZpath's Revolutionary pTau217 Antibody Wins Recognition

ALZpath, Inc., a front-runner in advancing diagnostic tools for Alzheimer's disease, proudly announced its recent accolade—the prestigious 'Diagnostics Innovation of the Year' awarded by BioTech Breakthrough. This recognition highlights the significant advancements brought about by ALZpath’s proprietary pTau217 antibody, which is pivotal for the early detection and monitoring of Alzheimer’s disease on a global scale.

The pTau217 antibody has quickly become integral to numerous commercially available blood tests. Its efficiency in detecting phosphorylated tau (pTau217)—a crucial biomarker associated with Alzheimer's—has been a game-changer. The antibody delivers remarkably high accuracy and sensitivity, identifying minimal concentrations of this biomarker well before clinical symptoms manifest. The incorporation of this antibody into both research and commercial settings has allowed for the earlier identification of patients, better monitoring of treatment responses, and crucial insights aimed at backing the development of new therapies.

CEO Mike Banville emphasized the company’s ongoing commitment to innovating Alzheimer’s diagnostics: "This recognition reflects our team's relentless commitment to transforming Alzheimer's diagnostics. Our pTau217 antibody is more than a scientific innovation; it is a powerful enabler that supports researchers and clinicians in detecting and monitoring Alzheimer’s disease with unrivaled preciseness. Our mission is to provide widely accessible blood tests that significantly improve outcomes for families facing the challenges of Alzheimer’s disease."

Since its introduction in 2023, the pTau217 antibody has been referenced in over 90 peer-reviewed publications, with 60 being original research articles, collectively yielding more than 34,000 data points from assays utilizing this innovative antibody.

About ALZpath

ALZpath is recognized as a leading developer of groundbreaking diagnostic solutions targeting Alzheimer's and related dementias. Their pTau217 antibody has become essential within the most sophisticated blood tests presently available, fundamentally changing how Alzheimer’s disease is researched, diagnosed, treated, and monitored. Collaborations with industry giants like Beckman Coulter Diagnostics, Roche, Alamar Biosciences, Bio-techne, and Quanterix have allowed ALZpath to advocate for new medicinal developments and enhance accessibility to early diagnostic and monitoring tools.

Moreover, partnerships with eminent laboratories, such as Neurocode, demonstrate ALZpath’s relentless pursuit to broaden its influence and reach. Their innovative contributions have earned them accolades, including being named one of Time Magazine’s Best Inventions of 2024, recognized as a Fast Company Most Innovative Company in 2025, and shortlisted for the Edison Award in the same year.

For those looking to discover more about ALZpath, further information is available on their website as well as on their LinkedIn, X, BlueSky, and Facebook pages. This award reinforces the unwavering dedication ALZpath has towards improving the lives of millions impacted by Alzheimer’s disease through accessible and effective diagnostic solutions.